Speaker Biography

Francis Amirtharaj

Gulf Medical University, UAE

Title: The spectrum of DYSF mutations in Indian dysferlinopathies

Francis Amirtharaj
Biography:

Dr. Francis Amirtharaj serves as an Assistant Professor/Research Scientist at the Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman, UAE since 2016. He earned his Ph.D. from the Madras University/CCMB and He has conducted research at Centre for Cellular and Molecular Biology, Hyderabad, India as a post-doctoral fellow.  He is expertise in various molecular biology techniques, such as next-generation sequencing (NGS), Sanger sequencing, real-time PCR etc. His current research interest to study the influence of p53 and its inactivation mutations in various cancer. He has ample teaching experience in Molecular Biology.

Abstract:

Dysferlin (DYSF) is a 237kDa transmembrane protein found in sarcolemma, known to facilitate membrane repair in skeletal muscles, muscle differentiation, membrane fusion, etc. The deficiency of DYSF due to mutations is one of the cause for Limb-Girdle Muscular Dystrophy 2B (LGMD2B), Miyoshi Myopathy (MM) and a distal anterior compartment myopathy (DMAT), which are collectively named dysferlinopathy. DYSF gene is located on chromosome 2 (2p13), encompasses 55 coding exons and spans 150 kb of genomic DNA. To evaluate the role of DYSF gene mutation(s) in Indian dysferlinopathies, we have performed both genetic and immunological analyses in 66 clinically defined cases. Western blot analysis of muscle specimens confirmed that all of them had dysferlin deficiency. All the 55 exons of DYSF were sequenced to find mutation(s) that are associated with dysferlinopathies. Sequence analysis of the dysferlin gene in these patients revealed a total of 84 variants. Of these, 51 were novel mutations that include 6 missense mutations; 6 silent mutations; 1 termination mutation; 3 frameshift mutations; 7 splice site variations; and 28 in intronic region and 33 previously reported mutations (5 missense; 7 silent; 1 termination mutation; 5 splice site; and 15 intronic region). This is the first extensive study of DYSF mutations in Indian dysferlinopathy samples. We have identified several novel and functionally significant mutation, which can be used as diagnostic markers.